Outcome of Board Meeting held on May 18, 2026 - Earnings Presentation for the quarter and year ended March 31, 2026
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma reported strong FY26 results with revenue of ₹48,587m (up 6.4% YoY) and operational PAT of ₹5,181m (up 50.3% YoY). Gross margins expanded by 310 basis points to 59.7%, while EBITDA margin improved by 140 basis points to 19.0%. The board recommended a dividend of ₹5 per share. The Ex-US markets delivered robust 21% YoY growth, offsetting the stable US business ($284m revenue, up 2% YoY). Net debt reduced by ₹1,972m on constant currency to ₹13,250m, with Net Debt/EBITDA improving to 1.55x from 1.90x in FY25. The company also appointed a new Executive Director to oversee global technical operations.
Strong profitability metrics and margin expansion signal effective cost management and operating leverage. The 50% PAT growth and dividend recommendation are positive for shareholders, while debt reduction improves the balance sheet strength.